argenx SE
ARGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeargenx SE argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. With a market capitalization of $64.25B, it sits in large-cap territory. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Market Cap
$64.25B
Beta
-0.03
P/E (TTM)
39.36
P/E (Fwd)
26.28
EPS (TTM)
$26.25
EPS (Fwd)
$39.31
ROE
23.6%
ROA
11.6%
Cash
$5.18B
Total Debt
$47.0M
Free CF
$761.8M
52W Change
34.5%
Annual Financials
Cash vs Debt
Where ARGX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ARGX finished 25.98% above its 150-day moving average ($837.70) and 25.14% above its 200-day moving average ($843.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARGX overbought or oversold?
At the September 3, 2026 close, ARGX's RSI(14) was 78.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.18B in cash and $47.0M in debt, ARGX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $761.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 23.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $410.7M (2022) to $4.15B (2025), reflecting a 911% increase over the period.
With a beta below 0.7, argenx SE typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ARGX has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence argenx SE's trajectory.